Shots:

• Vividion to receive $1.5B up front & $500M milestone while Bayer to get full rights to Vividion’s discovery platform which consists of chemoproteomic screening technology- a data portal- and a chemistry library. The transaction is expected to close in Q3’21
• The acquisition will strengthen Bayer’s drug discovery capabilities & expand it into new modalities. The acquisition will also increase the value of Vividion’s pipeline
• Vividion’s technology has the potential to expand into additional indications as it is already proved in oncology & immune-related diseases in preclinical studies

| Ref: Bayer | Image: The Business Journals